propiolactone has been researched along with Benign Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| HAYASHI, H; LOGRIPPO, GA | 1 |
1 review(s) available for propiolactone and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
2 other study(ies) available for propiolactone and Benign Neoplasms
| Article | Year |
|---|---|
β‑Propiolactone.
Topics: Animals; Carcinogens; Disinfectants; Female; Humans; Male; Neoplasms; Occupational Exposure; Propiolactone | 2011 |
Inactivation of vacuolating virus (SV 40) by betaprone. II. Evaluation of the oncogenic properties of SV 40 in hamsters after inactivation with betaprone.
Topics: Animals; Antiviral Agents; Cricetinae; Lactones; Neoplasms; Neoplasms, Experimental; Oncogenic Viruses; Propiolactone; Simian virus 40; Tissue Culture Techniques | 1963 |